publication venue for Plasma metabolites as biomarkers of survival in head and neck cancer patients undergoing pembrolizumab and cabozantinib 2025 Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma 2017
